- Tipifarnib (Zarnestra)
- GGsTop
- FK866 (APO866)
- PF-04620110
| LB42708Selective FTase inhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 99.78%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Description | LB42708 is a selective inhibitor of farnesyltransferase (FTase) with IC50 values of 0.8, 1.2 and 2.0 nM for H-Ras, N-Ras and K-Ras4B, respectively. | |||||
| Targets | FTase | Ftase | Ftase | |||
| IC50 | 0.8 nM (H-Ras) | 1.2 nM (N-Ras) | 2 nM (K-Ras4B) | |||
LB42708 Dilution Calculator
calculate
LB42708 Molarity Calculator
calculate
| Cas No. | 226929-39-1 | SDF | Download SDF |
| Canonical SMILES | C1COCCN1C(=O)C2=CN(C=C2C3=CC=CC4=CC=CC=C43)CC5=CN=CN5CC6=CC=C(C=C6)Br | ||
| Formula | C30H27BrN4O2 | M.Wt | 555.46 |
| Solubility | ≥22.75mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
LB42708 is a selective inhibitor of farnesyltransferase (FTase) with IC50 value of 0.8nM [1].
LB42708 is a nonpeptide pyrrole-based FTase inhibitor with high potency and selectivity. It inhibits the farnesylation of H-ras, N-ras and K-ras4B in vitro with IC50 values of 0.8nM, 1.2nM and 2nM, respectively. To the related enzyme geranylgeranyltransferase I, LB42708 shows no significant inhibition with IC50 value of 100μM. In cultured RAW264.7 cell line, LB42708 potently reduces the farnesylated p21ras stimulated by LPS and IFN-γ with IC50 value of ~ 10nM. Besides that, the HUVEC cells treated with LB42708 shows inhibition of cell proliferation and migration induced by VEGF. LB42708 inhibits the VEGF-induced DNA synthesis with IC50 value of 75nM and also inhibits VEGF-induced formation of the GTP-bound form of Ras with IC50 values of 50nM. In addition, it affects the tube-like structure formation. Furthermore, the administration of LB42708 can suppress tumor growth both in Ras-mutated HCT116 and wild-type Caco-2 xenograft models [1, 2].
References:[1] Na H J, Lee S J, Kang Y C, et al. Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21ras-dependent NF-κB activation. The Journal of Immunology, 2004, 173(2): 1276-1283.[2] Kim C K, Choi Y K, Lee H, et al. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways. Molecular pharmacology, 2010, 78(1): 142-150.
